Picton Mahoney Asset Management Grows Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Picton Mahoney Asset Management increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 50.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 633,149 shares of the company's stock after purchasing an additional 213,041 shares during the quarter. Picton Mahoney Asset Management owned 0.06% of Teva Pharmaceutical Industries worth $13,953,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Diversify Advisory Services LLC raised its position in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after purchasing an additional 496 shares during the period. Sanctuary Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after acquiring an additional 664 shares during the period. Metis Global Partners LLC increased its position in shares of Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after acquiring an additional 860 shares during the period. DGS Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after acquiring an additional 872 shares during the period. Finally, Williamson Legacy Group LLC increased its position in shares of Teva Pharmaceutical Industries by 1.7% in the fourth quarter. Williamson Legacy Group LLC now owns 57,824 shares of the company's stock valued at $1,274,000 after acquiring an additional 979 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Stock Down 1.4 %

NYSE:TEVA traded down $0.24 during mid-day trading on Tuesday, hitting $16.48. 9,443,030 shares of the company's stock were exchanged, compared to its average volume of 9,403,697. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The business has a fifty day moving average price of $18.09 and a 200 day moving average price of $18.26. The company has a market cap of $18.68 billion, a PE ratio of -11.36, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Friday, March 7th. Finally, Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.43.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares of the company's stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.